

## Author Index

- A**  
Abdennur, N, 45  
Almouzni, G, 1  
Anderson, EC, 279
- B**  
Bartolomei, M, 369  
Baumann, K, 394, 413, 416  
Bettencourt-Dias, M, 372  
Bian, Q, 279  
Biebricher, A, 187  
Black, BE, 249  
Blobel GA, 37  
Bloom, K, 101, 375  
Brejc, K, 279
- C**  
Calvo, JA, 339  
Cantor, SB, 339  
Chan YW, 207  
Cheeseman, I, 378  
Chen, P, 25  
Chen, X, 305  
Colaiácovo, MP, 223, 381
- D**  
DeLuca, JG, 91  
de Massy, B, 384  
Desai, A, 101, 386  
Dimitrova, YN, 83  
Doshi A, 101  
Durocher, D, 389
- F**  
Feng, W, 329  
Field, CM, 165  
Friedman, B, 101  
Fudenberg, G, 45  
Funabiki, H, 173
- G**  
Galupa, R, 267  
Ganier, O, 137  
Gasser, SM, 15  
Gleason, RJ, 305  
Goloborodko, A, 45  
Gudla, PR, 57
- H**  
Harrison SC, 83  
Heard, E, 267  
Henikoff, S, 71, 391  
Hetzer, M, 394  
Hickson, ID, 187, 397  
Hinshaw SM, 83  
Hirang, T, 157  
Hsu SC, 37  
Hunter N, 235
- I**  
Imakaev, M, 45
- J**  
Jagannathan, M, 319  
Jasin, M, 329, 400  
Jenness C, 173  
Jenni, S, 83  
Johnson, WL, 349
- K**  
Kahney, EW, 305  
Kasinathan, S, 71  
Kim, J, 259  
Kim, T, 101  
Kwon, M, 349
- L**  
Lampson, MA, 249  
Lara-Gonzalez, P, 111  
Lawrimore, J, 101  
Li, G, 25  
Liu, H, 197  
Liu, S, 349
- M**  
Meyer, BJ, 279  
Mirny, LA, 45, 403  
Misteli, T, 57  
Mitchison, TJ, 165, 406  
Miyazaki, S, 259  
Moorefield, B, 369, 397, 403
- N**  
Nabais, C, 123  
Nagaoka, SI, 213  
Nakayama, K, 57  
Nicetto, D, 197  
Nigg, EA, 137
- P**  
Page, D, 363  
Palozoa, KC, 197  
Pegoraro, G, 57  
Pellman, D, 349  
Petermann, EJG, 187  
Podsypanina, K, 1
- R**  
Ranjan, R, 305
- S**  
Saito, TT, 223  
Saitou, M, 213  
Sakuno, T, 259  
Sarlós, K, 187  
Schnerch, D, 137  
Sever, R, 391, 406  
Shintomi, K, 157  
Sitbon, D, 1  
Spradling, AC, 293  
Stearns, T, 145, 409  
Straight, A, 413  
Szewczak, L, 378, 381, 384, 386, 400
- T**  
Talbert, PB, 71  
Thakur, J, 71
- V**  
Valverde, R, 83
- W**  
Walsh, JT, 145  
Watanabe, Y, 259  
West, SC, 207  
Witkowski, J, 372, 375, 389, 409  
Wuite, GJL, 187
- X**  
Xie, KT, 349
- Y**  
Yadav, T, 1  
Yamashita, YM, 319, 416
- Z**  
Zaret, KS, 197  
Zeller, P, 15  
Zierhut, C, 173



## Subject Index

- A**
- ABRO1, 333
  - ACD. *See* Asymmetric cell division
  - Adenomatous polyposis coli (APC), 18, 141
  - AIR-2, 228
  - Anaphase-promoting complex/cyclosome (APC/C)
    - inactivation in late mitosis, 116
    - initiation during G<sub>2</sub>, 113
    - overview, 111, 350, 386–387
    - prospects for study, 116–117
    - regulation in mitosis
      - kinetochore mediation
        - Cdc20 activation through dephosphorylation, 134, 387
      - inhibition by spindle assembly checkpoints, 114–116
      - integration of activation and inhibition mechanisms, 116
      - phosphorylation, 113–114
      - structure, 112
      - ubiquitination mechanism, 112–113
  - ANT-C, 298, 302
  - APC. *See* Adenomatous polyposis coli
  - APC/C. *See* Anaphase-promoting complex/cyclosome
  - ASF, 179
  - Asf1, 4, 161
  - Ash1, 312
  - Aster
    - chromosome passenger complex and centralspindlin recruitment, 167–170
    - growth and recruitment of furrow-stimulating complexes, 166–167
  - Asymmetric cell division (ACD), 305, 309, 311, 313–315, 416
  - ATF5, 151
  - ATM, 210, 241
  - ATR, 240–242
  - ATRIP, 242
  - ATRX, 3–5, 355
  - Aurora kinases
    - Aurora A kinase
      - functions at kinetochore, 93–94, 96
      - overview, 92
      - recruitment to centromere/kinetochore region, 94–95
    - Aurora B kinase, 91–92, 95–96, 177–179
    - Aurora C kinase, 92
    - overview, 91–92
    - substrate specificity, 95–96
  - Azidothymidine (AZT), 238–240
  - AZT. *See* Azidothymidine
- B**
- BAF. *See* Barrier-to-autointegration factor
  - Barrier-to-autointegration factor (BAF), 351
  - Basal body
    - biogenesis
      - de novo assembly, 126–130
      - deuterosome-mediated biogenesis, 124–126
      - duplication, 123–124
      - mechanisms, 130–131
      - prospects for study, 132–133
    - evolutionary history, 131–132
    - overview, 123
  - Bdf1, 39
  - Bdf2, 39
  - BET proteins
    - chromatin domain boundary formation, 40–41
    - insulator and architectural function, 39–40
    - local chromatin environment regulation, 38–39
    - nuclear structure maintenance, 37–38
    - overview, 37
    - prospects for study, 41
  - Bicentriole, 126, 128–129
  - bioRxiv*, 404–405
  - Blepharoplast, 126, 129–130
  - BLM, 188–190, 192, 207, 210
  - Bloom syndrome, 207
  - BLZ-2*, 364
  - BMP. *See* Bone morphogenetic protein
  - BOD1L, 333
  - Bone morphogenetic protein (BMP), female
    - germ cell sex determination and meiotic induction signaling, 217–219
  - Borealin, 92
  - BRCA1, 21, 242, 330, 333, 339–343
  - BRCA2
    - deficiency
      - consequences, 330–331
      - degradation factors and fork dynamics, 340–343
      - p53 induction, 331–332
    - homologous recombination role, 329–330, 357, 400–401
    - replication fork protection, 329–330, 339–340
    - therapeutic targeting, 334–335
    - tumor suppression, 329, 339
  - BRD-1, 21
  - BRD2, 37–40
  - BRD3, 37–39
  - BRD4, 37–39
  - BRDT, 38
  - BRG1, 16
  - BTRR complex, 190–191
  - Bub1, 114, 116, 200, 260, 262–263
  - Bub3, 115, 260, 262
  - BX-C, 298, 302
- C**
- Cabin1, 4
  - CAF-1, 2, 4
  - Cardiac stem cell, 314
  - CBF3, 72
  - CD113, 315
  - Cdc20. *See* Anaphase-promoting complex/cyclosome
  - CDC42, 252, 254–255, 354
  - Cdc48, 178
  - Cdh1, 113, 116
  - Cdk1, 113–114, 159
  - Cdk5, 116
  - CED-3, 230
  - CENP-A, 3–7, 9–10, 29–30, 71, 75–76, 93, 188, 249–252, 255–256, 309, 354–355
  - CENP-B, 71, 75–76, 79, 250, 252, 354–355
  - CENP-C, 71, 76, 249–250, 252, 255–256
  - CENP-N, 29–30
  - CENP-T, 76
  - CENP-TWSX, 76
  - Centralspindlin, aster recruitment, 167–170
  - Centrin, 126–127, 130–132
  - Centriole
    - biogenesis
      - de novo assembly, 126–130
      - deuterosome-mediated biogenesis, 124–126
      - duplication, 123–124
      - mechanisms, 130–131
      - prospects for study, 132–133
    - compound microtubule structure, 146–148
    - evolutionary history, 131–132
    - overview, 123, 145–146, 372–374
    - structure, 409–412
    - triplet microtubules
      - elongation, 150–151
      - formation
        - cartwheel role, 149–150
        - centriolar tubulin features, 148–149
        - overview, 148
        - functions, 151

- Centromere  
asymmetric sister chromatid  
distinguishing, 308–309  
cenH3 nucleosome positioning at  
satellite centromeres, 75  
cohesion protection in meiosis  
Bub1 role, 262–263  
kinetochore geometry, 260–261  
MEIKIN role in mice, 261–262  
mono-orientation of kinetochores in  
yeast  
Moa1, 261–263  
monopolin, 261  
Rec8, 261  
overview, 259  
evolutionary plasticity of chromatin  
budding yeast, 72–73  
*Caenorhabditis elegans*, 74  
fission yeast, 73–64  
humans, 76  
insects, 74–75  
prospects for study, 78–79  
overview, 71–72, 250–252  
spring, 375–377  
ultrafine DNA bridges, 188  
Centromere drive  
oocyte meiotic spindle, 252, 254–255  
overview, 249–250  
prospects for study, 256, 391–393  
Centrosome  
aberrations  
cancer studies, 137–143  
chromosome segregation fidelity  
impact, 138–139  
overview, 138  
tissue architecture impact, 139–142  
duplication cycle, 138  
nonrandom sister chromatid segrega-  
tion, 309–311  
overview, 137  
CEP120, 150  
CEP135, 148, 132  
Cep152, 126  
CEP295, 150  
CHD4, 341  
CHK1, 241  
CHK2, 210, 240–242  
Chromatin fiber  
epigenetic regulation by chromatin  
factors, 28–30, 354–355  
nuclear organization, 31–32  
prospects for study, 32–33  
single-molecule studies of dynamics,  
27–28  
structure, 25–27  
Chromocenter  
bundling proteins, 321  
function, 322–323  
genome encapsulation, 321–322  
ChromoShake, 101  
Chromosome loop extrusion. *See also*  
Topologically associating  
domain  
energy budget, 52  
experimental testing of model, 48–50  
model testing challenges, 47  
overview, 352–353  
polymer model with barrier elements,  
45–48  
RotoStep simulation  
condensin stepping, 106  
convolution, 103, 105  
model assumptions, 102  
overview, 101–102  
parameters, 104  
processive motion consequences on  
tethered substrate with *cis*-  
and *trans*-binding, 102–103  
prospects, 106–108  
strand compaction via multiple  
condensins, 105  
tension and loop formation, 105–106  
single-molecule experiments, 50–53  
walking mechanism, 51  
Chromosome passenger complex (CPC)  
aster recruitment, 167–170, 351  
chromatin proteomic regulation,  
178–182  
spindle assembly role, 176–178  
CK1, 261  
Cnn1, 86–87  
Cnp1, 261  
Common fragile sites, ultrafine DNA  
bridges, 188  
COMPASS, 228  
Condensin  
chromatid axis formation, 158–159  
condensin I versus condensin II  
function, 158  
identification in *Xenopus* egg extracts,  
157–158  
mitotic chromatids  
assembly without nucleosomes,  
160–161  
nucleosome cross talk with conden-  
sins, 161  
nucleosome dynamics during  
assembly, 159–160  
reconstitution, 159  
RotoStep simulation of chromosome  
loop extrusion, 101–103,  
105–108  
CP110, 127, 150  
CPAP, 148, 150  
Cpap, 126, 132  
CPC. *See* Chromosome passenger complex  
CpG islands, 15  
Crystallin, 395  
Csm1, 261  
CTCF, 39–41, 45, 47–48, 50–51, 268–271,  
274–275, 352  
CTIP, 333  
Cummings lecture, 363–366  
**D**  
D1, 321–322  
Dam1, 84–87  
DAPI, 160  
DASH, 84–86  
DAXX, 3–5, 10, 29, 355  
*DC10*, 364  
Desmin, 314  
Deup1, 126  
DNA methyltransferase (DNMT), 21  
DNA replication  
asymmetry, 306  
histone recycling and cell fate, 306–308  
DNMT. *See* DNA methyltransferase  
Dosage compensation  
dosage compensation complex,  
279–281, 355  
H4K20me1, 281–285  
JmjC role, 282–285  
overview, 279–281  
Dppa2, 178  
DPY-21, 282–288  
DRAQ5, 32  
Dsn1, 87–88  
Duo1, 86  
**E**  
ELYS, 176  
EME1, 207–208  
Emerin, 228  
Emi1, 113  
Emi2, 113  
Enhancer, mitotic transcription, 203–204  
*Epha4*, 274  
ERBB2, 140  
ERCC1, 207–208, 238  
EXO1, 333  
EXO1, 341  
EZH2, 333, 340–341  
**F**  
FACT, 28–29, 160, 174  
FAN1, 340  
FANC2, 210–211  
FANCA, 339  
FANCD2, 339–340, 401  
FANCF, 345  
FANCM, 190, 229, 340  
FGF9, 215  
53BP1, 138, 210, 332, 401  
FISH. *See* Fluorescence in situ  
hybridization  
*FLP*, 364  
Fluorescence in situ hybridization (FISH)  
overview, 57–58  
spot detection in high-throughput  
imaging  
cell culture, 58  
code implementation and avail-  
ability, 60  
convolutional neural network  
(SpotLearn), 59–60  
imaging, 58–59  
nucleus segmentation and filtering,  
59  
oligo probes, 58  
prospects, 67–69  
quantitative assessment, 60  
random forest classifier versus deep  
convolutional neural  
network, 65–67

- random forest filtering for nuclear segmentation, 61, 63–64
- Fork protection (FP)  
BRCA1, 339–340  
BRCA2, 329–330, 339–343  
cell fitness contributions, 334  
FANC proteins, 339–340  
nucleases in nascent strand degradation, 333–334  
RAD51, 332–333, 339–340  
rewired protection mechanisms in BRCA deficiency, 341–346
- FoxA1, 198  
FP. *See* Fork protection
- G**
- GATA1, 40  
GEN1, 208–209
- H**
- H2A.X-F, 160  
Haspin, 180  
HDAC3, 21  
Hec1, 91, 93, 95  
Heterochromatin  
DNA damage and repair role, 16  
overview, 15–16  
repair factors and transcriptional silencing, 20–21  
repetitive elements, 17–20  
RNA:DNA hybrids, 16–17, 19–20, 411–413  
HIM-18, 227, 229  
Histone H1, chromatin fiber formation, 26–27  
Histone H3  
H3K9 methylation, 18–19  
variants  
chromatin fiber effects, 29  
development role, 7, 9  
dynamics, 3  
species comparison of H3.3  
variants, 8  
Histone H4, H4K20me1  
chromosome compaction in germ cells, 287–288  
dosage compensation role, 281–284  
remodeling of X-chromosome topology, 285–287  
HJ. *See* Holliday junction  
HJURP, 3–7, 10, 252  
HLTf, 341, 344  
HMGA1, 321–322  
*Hmr*, 323  
HO endonuclease, 312  
Holliday junction (HJ)  
homologous recombination-ultrafine bridges and chromosome aberrations, 210  
processing mechanisms and regulation, 207–209  
resolvase deficiency model system, 209  
Homologous recombination. *See* BRCA2; Holliday junction
- HORMAD proteins, 241–243  
*HoxA*, 272  
HP1, 180, 309  
HP1a, 17  
HSF1, 321  
Hst2, 179
- I**
- ICR. *See* Imprinting control region  
*Ihh*, 274  
Imprinting control region (ICR), 355, 369–370  
INCENP, 92, 94, 167, 176–178  
INO80, 16  
Ip11, 87
- J**
- JmjC, 282–288
- K**
- KAP1, 210  
Kif4a, 167–168  
Kif20A, 167–168  
KIF24, 150  
Kinetochores  
anaphase-promoting complex/  
cyclosome mediation  
Cdc20 activation through dephosphorylation, 134  
inhibition by spindle assembly checkpoints, 114–116  
integration of activation and inhibition mechanisms, 116  
Aurora A kinase  
functions at kinetochore, 93–94, 96  
recruitment, 94  
cell cycle regulation, 386–388  
geometry in centromere cohesion  
protection in meiosis  
mono-orientation of kinetochores in yeast  
Moa1, 261–263  
monopolin, 261  
Rec8, 261  
overview, 260–261  
inner complex in young human centromeric repeats, 76  
microtubule attachment stability regulation, 91  
overview, 378–380  
yeast structure and function  
adapters, 86–87  
intercomplex connections, 87–88  
microtubule attachment, 83–86  
KNL1, 260, 262  
Knl1, 114–115
- L**
- L1ORF1, 237–238, 240  
L1ORF2, 240, 243  
LAB-1, 228  
Lap2, 228  
LATS2, 138  
*Lhr*, 323  
LINC, 311  
LINE-1  
derepression  
advantages in germline, 240  
early oocyte attrition, 236–237  
oogenesis defects, 238–240  
overview of effects, 18, 237  
repression layers, 237–238  
Loop extrusion. *See* Chromosome loop extrusion  
Lrs4, 261  
LSD-1, 283
- M**
- Mad1, 115–116  
Mad2, 115–116  
MAN1, 228  
*MAT*, 312  
Mau2, 50  
MCAK, 176, 181, 256  
MDC1, 210, 243  
MDM2, 138  
MeCP2, 321  
MEIKIN, 261–263  
Meiosis. *See also* Centromere drive; Oocyte attrition  
centromere cohesion protection in meiosis  
Bub1 role, 262–263  
kinetochore geometry, 260–261  
MEIKIN role in mice, 261–262  
mono-orientation of kinetochores in yeast  
Moa1, 261–263  
monopolin, 261  
Rec8, 261  
overview, 259  
crossovers  
*Caenorhabditis elegans*  
class II crossover pathway, 229–230  
inducible single double-strand break system, 228–229  
patterning, 227–228  
sexual dimorphism in crossover regulation, 230  
classes, 224  
localization, 381–383  
molecular steps in formation, 223–224  
regulation  
assurance/obligate crossover, 224–225  
autosomes and sex chromosomes, 230–231  
homeostasis, 226  
interference, 225–226  
invariance, 226–227  
patterning/centromere effect, 227  
epigenetic reprogramming in female meiosis, 238

Meiosis (*Continued*)

female germ cell sex determination and  
meiotic induction signaling,  
217–219  
germ cell specification in mammals,  
213–214  
implementation during oogenesis  
and spermatogenesis,  
215–216  
oocyte meiotic spindle, 252, 254–255  
sex determination and meiotic  
initiation in mammals,  
214–215

Mer3, 224  
Micronuclei, 417  
MIND, 86–87  
Mis6, 309  
MKLP1, 167  
MKLP2, 167–168  
MLH1, 230  
MLL3, 333  
MLL4, 333  
Moa1, 261–263  
*MOM-4U*, 364  
Monopolin, 261  
Mph1, 260, 262–263  
Mps1, 115  
MRE11, 329, 333, 340–341  
MSH2, 345  
Msh4, 224  
Msh5, 224  
MUS81, 207–209, 229, 333–335, 343  
*Myc*, 272  
Myf5, 314

**N**

NANOS2, 215  
Nap1, 159  
NASP, 2, 4  
NCP. *See* Nucleosome core particle  
NDC80, 91, 309  
Ndc80, 83–85, 87–88, 115  
Nek2A, 114  
Ninein-like protein (NLP), 140–142  
Nipbl, 48, 50  
Nkx2.5, 314  
NLP. *See* Ninein-like protein  
Non-small cell lung cancer (NSCLC),  
315  
NPC. *See* Nuclear pore complex  
Npm2, 1  
NSCLC. *See* Non-small cell lung cancer  
Nuclear pore complex (NPC), 173–174,  
176, 182  
Nucleosome core particle (NCP), 25  
Nucleosome  
mitotic chromatid assembly  
assembly without nucleosomes,  
160–161  
nucleosome cross talk with  
condensins, 161  
nucleosome dynamics during  
assembly, 159–160  
reconstitution, 159  
mitotic progression regulation

mass spectrometry analysis of  
binding proteins, 173–174  
microtubule dynamics and nuclear  
envelope formation  
coordination by chromatin  
factors, 178  
RCC1–Ran pathway, 174–176  
*Xenopus* egg extract studies, 173  
Nuf2, 83–84, 309  
NUP107

**O**

OFD1, 150  
Oocyte attrition  
early oocyte attrition  
advantages, 240  
LINE-1 element derepression,  
236–237  
epigenetic reprogramming in female  
meiosis, 238  
late oocyte attrition  
DNA damage response pathway  
triggering, 240–241  
meiosis-specific HORMA-domain  
protein roles, 241–242  
meiotic silencing, 242–243  
physiological late oocyte attrition  
and HORMADs, 243  
LINE-1 element derepression and  
oogenesis defects,  
238–240  
overview, 235–236  
prospects for study, 243  
Oogenesis. *See* Centromere drive; Meiosis  
Op18, 176, 178  
ORCA, 21  
ORF2, 237

**P**

p53, 5, 7, 138, 149, 331–332, 400–401,  
410  
p97, 178  
PARP, 329–330, 334–335, 340–341,  
343–344, 346, 357  
*Pax3*, 274  
*Pax7*, 314  
PCM. *See* Pericentriolar material  
PCNA, 293, 344  
Pds5a, 50  
Pds5b, 50  
Pericentriolar material (PCM), 350–351  
Pericentromeric satellite DNA. *See* Satellite  
DNA  
PGC. *See* Primordial germ cell  
PICH, 187–189, 192, 210, 357, 397–399  
PLK1, 260, 262, 399  
Plk1, 116  
PLK4, 138, 140–141  
Plk4, 125–127, 131  
Plo1, 262–263  
Poc1, 132  
POC5, 150–151  
Poc16, 147  
POLD3, 343

Polytene chromosome  
genetic regulation diversification, 302  
genome instability and Dipteran  
evolution, 302  
overview, 293–294  
prospects for study, 302  
unfinished replication regions  
coordination of replication and  
transcription, 300–301  
mapping, 295–299  
replication timing role, 301–302  
topologically associating domain  
association, 299–300  
PP2A, 260  
PRC1, 177  
PRDM9, 356, 384–385  
Primordial germ cell (PGC)  
derivation in vitro, 216  
expansion culture, 216  
female germ cell sex determination and  
meiotic induction signaling,  
217–219, 356  
specification, 213–214  
PTIP, 333

**R**

RA. *See* Retinoic acid  
RAC, 252  
Rad21, 49, 259  
RAD51, 211, 329–330, 332–334, 339–341,  
344–345  
Rad51, 224  
RAN, 252, 254–255  
Ran, 174–176, 182  
RanBP1, 175  
RASD-51, 231  
RCC1, 174–176, 182  
rDNA loci, ultrafine DNA bridges, 189  
REC-8, 228  
Rec8, 259, 261  
Recombination intermediates. *See* Holliday  
junction  
Replication fork protection. *See* Fork  
protection  
Replication protein A (RPA), 210  
Retinoic acid (RA), sex determination and  
meiotic initiation  
in mammals, 215, 217–219  
RHAMM, 95  
RIF1, 189–190, 399  
RMII, 207  
Rmi1, 224  
RMI2, 207  
RMII, 190  
RNA polymerase II, mitotic transcription,  
198–200, 203–204  
ROSBIN, 282–283  
RotoStep. *See* Chromosome loop  
extrusion  
RPA, 190  
RPA. *See* Replication protein A  
RSC, 16  
RTEL-1, 229  
RTTN, 150  
RuvC, 207

S

SAMHD1, 237–238  
SAS-6, 138, 409  
Sas6, 126, 130, 132  
SASS6, 145–146, 148  
Satellite DNA  
  chromocenter  
    bundling proteins, 321  
    function, 322–323  
    genome encapsulation, 321–322  
  history of study, 319–320  
  pericentromeric satellite DNA  
    repression, 320  
    roles, 320–321  
  speciation role, 323  
Sca-1, 314  
SDC-2, 283  
Securin, 259  
SET-1, 281  
Set1, 228  
Sgo1, 188, 259–260, 262–263  
Sgs1, 224  
Sir2, 225  
SIR3, 39  
SIRT1, 39  
SIRT2, 181  
Sister chromatid segregation  
  asymmetric cell division in *Drosophila*,  
    313  
  centrosome role, 309–311  
SLX1, 207, 227–229  
Slx1, 224  
SLX4, 207–209, 227, 229, 335  
Slx4, 224  
Slx5, 225  
Slx8, 225  
SMARCAL1, 334, 340–341,  
  343–344  
SMC proteins, 352–353, 375  
SOX9, 215  
Spc7, 260, 262–263  
Spd5, 131  
Spermatogenesis. *See* Meiosis  
SPO11, 238, 240, 384–385  
Spo11, 224  
Spo13, 261, 263  
Spo16, 224  
Spo22, 224  
SpotLearn. *See* Fluorescence in situ  
  hybridization  
SRp20, 179  
SRY, 215  
STIL, 138  
Stil, 126  
SUMO, 224

Survivin, 92  
Swi6, 262

T

TAD. *See* Topologically associating domain  
TAp63, 240–241, 243  
Tau, 177  
Telomere, ultrafine DNA bridges, 188–189  
TEX19.1, 237  
*Tfap2c*, 272, 274  
TIP-60, 20  
TLS. *See* Translesion synthesis  
Top3, 224  
TOPBP1, 190, 242  
Topo II, 159, 162, 187–190  
Topologically associating domain (TAD)  
  cell cycle dynamics, 269–270  
  CTCF in insulation and loop formation,  
    269  
  definition, 268  
  discovery, 267  
  loop extrusion models, 269  
  organization mechanisms and dynam-  
    ics, 268–270  
  overview, 267–268  
  preimplantation development dynamics,  
    270  
  regulatory landscapes  
    chromatin states, 272  
    development role, 272–274  
    diseases, 274–275  
    enhancer–promoter communication,  
      270–271  
    mammalian genome evolution, 274  
    overview, 270  
    transcriptional co-regulation, 271–  
      272  
  unfinished replication regions in poly-  
    tene chromosomes, 299–300  
TPX2, 92, 94–95, 131, 174  
Translesion synthesis (TLS), fork protec-  
  tion, 345–346  
TREX1, 237–238  
TRF1, 188  
TRF2, 188  
TTBK2, 150  
Tubulin B3, 396

U

UBN1, 4  
UBR2, 237  
UFBs. *See* Ultrafine DNA bridges  
Ultrafine DNA bridges (UFBs)  
  aberrations, 192, 357

centromeres, 188  
common fragile sites, 188  
homologous recombination-ultrafine  
  bridges and chromosome  
  aberrations, 210  
origins, 187–188  
rDNA loci, 189  
recognition and processing proteins  
  BLM, 189–190  
  FANCM, 190  
  PICH, 189  
  RIF1, 190  
  RPA, 190  
  TOPBP1, 190  
  Topo II, 190  
reconstitution, 190–192  
telomeres, 188–189  
Unfinished replication. *See* Polytene  
  chromosome; Topologically  
  associating domain  
USP38, 138

W

Wap1, 50  
WAPL, 352  
Wip1, 86  
*Wnt6*, 274

X

XIAP, 177  
*Xic*, 270, 272  
*XIST*, 289  
*Xist*, 270  
*xol-1*, 283–285  
XPF, 17  
XPF, 207–208, 224, 238  
XPF-1, 229  
XPG, 17  
XRN-2, 20

Y

Y chromosome, evolution, 363–366

Z

ZHP-3, 229  
Zip1, 224  
Zip2, 224  
Zip3, 224  
ZNRANB3, 341, 343–344

